Kwaku Poku Asante, Don P Mathanga, Paul Milligan, Samuel Akech, Abraham Oduro, Victor Mwapasa, Kerryn A Moore, Titus K Kwambai, Mary J Hamel, Thomas Gyan, Nelli Westercamp, Atupele Kapito-Tembo, Patricia Njuguna, Daniel Ansong, Simon Kariuki, Tisungane Mvalo, Paul Snell, David Schellenberg, Paul Welega, Lucas Otieno, Alfred Chimala, Edwin A Afari, Philip Bejon, Kenneth Maleta, Tsiri Agbenyega, Robert W Snow, Madaliso Zulu, Jobiba Chinkhumba, Aaron M Samuels
BACKGROUND: The RTS,S/AS01E malaria vaccine (RTS,S) was introduced by national immunisation programmes in Ghana, Kenya, and Malawi in 2019 in large-scale pilot schemes. We aimed to address questions about feasibility and impact, and to assess safety signals that had been observed in the phase 3 trial that included an excess of meningitis and cerebral malaria cases in RTS,S recipients, and the possibility of an excess of deaths among girls who received RTS,S than in controls, to inform decisions about wider use...
April 4, 2024: Lancet